TY - JOUR
T1 - Apolipoprotein A-1 in umbilical cord blood of newborn infants
T2 - Relation to gestational age and high-density lipoprotein cholesterol
AU - Parker, C. Richard
AU - Fortunato, Stephen J.
AU - Carr, Bruce R.
AU - Owen, John
AU - Hankins, Gary D.V.
AU - Hauth, John C.
PY - 1988/4
Y1 - 1988/4
N2 - Apolipoprotein A-l (Apo A-l) is the major protein constituent of high-density lipoprotein (HDL) and Apo A-l plays an important role in lipid metabolism and may be protective against atherosclerosis in adults. However, little is known about HDL and Apo A-l in the developing human fetus. Herein we investigated the relationship of Apo A-l levels in umbilical cord blood at delivery to gestational age and HDL cholesterol. Fetal plasma levels of Apo A-l, which were not correlated with those in maternal plasma, were significantly lower among newborns delivered at 21-26 wk gestation (52 ± 4.4 tag/ dl, mean ± SE) than in those delivered at 33-34 wk gestation (87 ± 5.8 mg/dl). Thereafter, the mean umbilical cord plasma levels of Apo A-l remained relatively constant (101 mg/dl at 39-40 wk of gestation). We found no significant correlations between Apo A-l levels and fetal sex, race, or delivery method. At equivalent gestational ages and birth weights, however, Apo A-l levels in white newborns tended to be lower than those in black infants. The Apo A-l/HDL cholesterol ratio in umbilical cord blood rose progressively from 2.5 (27-28 wk gestation) to 3.8 at term, due largely to increased Apo A-l levels but little change in the mean HDL cholesterol levels, which ranged from 22-24 mg/dl at each gestational period. These results are suggestive that fetal plasma Apo A-l is derived solely from fetal sources and that the rate of production and/or clearance of Apo A-l is altered during the latter third of human intrauterine development.
AB - Apolipoprotein A-l (Apo A-l) is the major protein constituent of high-density lipoprotein (HDL) and Apo A-l plays an important role in lipid metabolism and may be protective against atherosclerosis in adults. However, little is known about HDL and Apo A-l in the developing human fetus. Herein we investigated the relationship of Apo A-l levels in umbilical cord blood at delivery to gestational age and HDL cholesterol. Fetal plasma levels of Apo A-l, which were not correlated with those in maternal plasma, were significantly lower among newborns delivered at 21-26 wk gestation (52 ± 4.4 tag/ dl, mean ± SE) than in those delivered at 33-34 wk gestation (87 ± 5.8 mg/dl). Thereafter, the mean umbilical cord plasma levels of Apo A-l remained relatively constant (101 mg/dl at 39-40 wk of gestation). We found no significant correlations between Apo A-l levels and fetal sex, race, or delivery method. At equivalent gestational ages and birth weights, however, Apo A-l levels in white newborns tended to be lower than those in black infants. The Apo A-l/HDL cholesterol ratio in umbilical cord blood rose progressively from 2.5 (27-28 wk gestation) to 3.8 at term, due largely to increased Apo A-l levels but little change in the mean HDL cholesterol levels, which ranged from 22-24 mg/dl at each gestational period. These results are suggestive that fetal plasma Apo A-l is derived solely from fetal sources and that the rate of production and/or clearance of Apo A-l is altered during the latter third of human intrauterine development.
UR - http://www.scopus.com/inward/record.url?scp=0023905555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023905555&partnerID=8YFLogxK
U2 - 10.1203/00006450-198804000-00002
DO - 10.1203/00006450-198804000-00002
M3 - Article
C2 - 3131725
AN - SCOPUS:0023905555
SN - 0031-3998
VL - 23
SP - 348
EP - 351
JO - Pediatric Research
JF - Pediatric Research
IS - 4
ER -